drugset / Trial / NCT06399003
Comparison Study of SIBP's MMR Vaccine Versus GSK MMR Vaccine in Children Aged 9-11 Months
Phase 3
Completed
1200 enrolled
Shanghai Institute Of Biological Products
Victoria Biomedical Research Institute · collab
RandomizedParallel-groupSingle-blindPrevention
Summary
To evaluate the Immunogenicity and Safety of Shanghai Institute of Biological Products Co., Ltd.'s Measles, Mumps and Rubella (MMR) Vaccine Compared to a Licensed and WHO Prequalified GSK MMR Vaccine in Healthy African Children, 9-11 Months of Age.
Timeline
- Start
- 2024-06-28
- Primary completion
- 2024-09-15
- Completion
- 2025-03-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Priorix | Vaccine | 0.5 ml | — |
| Subject | SIBP MMR Vaccine | Vaccine | 0.5 ml | — |
| Subject | Yellow Fever Vaccine | Vaccine | 0.5 ml | — |